Please login to the form below
CoronaVac
This page shows the latest CoronaVac news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Vaxzevria trial provides further support for protection against COVID-19 variants
antibody levels following a primary vaccine series using Sinovac Biotech’s Coronavac.
Latest news
-
Sinovac’s COVID-19 vaccine receives WHO emergency use listing
The WHO has listed Sinovac’s CoronaVac vaccine for emergency use in adults aged 18 years and older as part of a two-dose regimen. ... Even though the clinical trials of CoronaVac enrolled few older adults aged over 60, the WHO said subsequent data
-
Sinovac’s COVID-19 vaccine demonstrates 50.4% efficacy in Brazilian trial data
The results from phase 1 and phase 2 trials, published in The Lancet Infectious Diseases, evaluated the CoronaVac vaccine in over 700 participants. ... Last month, researchers in Turkey said that the CoronaVac vaccine was 91.25% effective, according to
-
Sinovac’s COVID-19 vaccine produces antibody response in mid-stage study
patients. The results from phase 1 and phase 2 trials, published in T he Lancet Infectious Diseases, evaluated the CoronaVac vaccine in over 700 participants. ... have 46 million doses of CoronaVac available in January.
-
Sinovac’s late-stage COVID-19 vaccine trial paused in Brazil
Previously, Sinovac released positive results from a phase 2 study of its COVID-19 vaccine candidate, CoronaVac, in which the vaccine induced detectable antibody-based immune responses in participants and also
-
Sinovac’s COVID-19 vaccine appears safe in older adults
participants. Individuals in the three groups were given two shots of low-, medium- and high-dose CoronaVac, respectively. ... Sinovac offered CoronaVac to around 2, 000-3, 000 employees and their families on a voluntary basis, said Weidong.
More from news
Approximately 3 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn
- Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn
- Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
- Novavax’s updated COVID-19 vaccine approved by FDA for emergency use
- Alzheimer’s Research UK awards Cardiff University researchers £387,000
- Actinic keratosis – a common skin condition that can lead to skin cancer
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
